QLHC Quantum Leap Healthcare Collaborative

Announcement

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

Stream videos of I-SPY's September 12 Press Conference

Video available of the I-SPY press event held September 12, 2018.

On September 12, 2018, the leadership of the I-SPY Trials program held a press conference at the National Press Club in Washington, DC to provide an update on their progress in breast cancer treatment and to highlight the importance of advanced platform trial designs such as I-SPY.

Highlights of the press event are provided below, or you can watch the entire event on youtube.

Introduction by Anna Barker, PhD, of Arizona State University and I-SPY's Executive Oversight Committee.

The FDA's Dr. Janet Woodcock on the importance of platform trials.

I-SPY Principal Statistician Dr. Don Berry on the new generation of clinical trials.

Penn's Dr. Angela DeMichele discusses I-SPY's impact on breast cancer treatment

I-SPY Principal Investigator Dr. Laura Esserman discusses I-SPY's achievements and next steps.

Vidya Balakrishnan, a patient participant in the I-SPY2 trial discusses her experience.

Dr. Barker's summary.

Media Contact:

Kristen Zeitzer
Quantum Leap Healthcare Collaborative
(855) 866-0505 x115
k.zeitzer@quantumleaphealth.org